JP2012529298A5 - - Google Patents

Download PDF

Info

Publication number
JP2012529298A5
JP2012529298A5 JP2012515109A JP2012515109A JP2012529298A5 JP 2012529298 A5 JP2012529298 A5 JP 2012529298A5 JP 2012515109 A JP2012515109 A JP 2012515109A JP 2012515109 A JP2012515109 A JP 2012515109A JP 2012529298 A5 JP2012529298 A5 JP 2012529298A5
Authority
JP
Japan
Prior art keywords
loop
antigen
domain
recombinant
domain monomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012515109A
Other languages
English (en)
Japanese (ja)
Other versions
JP5894528B2 (ja
JP2012529298A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/038008 external-priority patent/WO2010144602A2/en
Publication of JP2012529298A publication Critical patent/JP2012529298A/ja
Publication of JP2012529298A5 publication Critical patent/JP2012529298A5/ja
Application granted granted Critical
Publication of JP5894528B2 publication Critical patent/JP5894528B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012515109A 2009-06-09 2010-06-09 抗原−ノロウイルスpドメインモノマーおよびダイマー、抗原−ノロウイルスp粒子分子、ならびにそれらの製造および使用法 Active JP5894528B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18556409P 2009-06-09 2009-06-09
US61/185,564 2009-06-09
US22469609P 2009-07-10 2009-07-10
US61/224,696 2009-07-10
PCT/US2010/038008 WO2010144602A2 (en) 2009-06-09 2010-06-09 Antigen-norovirus p-domain monomers and dimers, antigen-norovirus p-particle molecules, and methods for their making and use

Publications (3)

Publication Number Publication Date
JP2012529298A JP2012529298A (ja) 2012-11-22
JP2012529298A5 true JP2012529298A5 (cg-RX-API-DMAC7.html) 2013-07-25
JP5894528B2 JP5894528B2 (ja) 2016-03-30

Family

ID=43309459

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012515109A Active JP5894528B2 (ja) 2009-06-09 2010-06-09 抗原−ノロウイルスpドメインモノマーおよびダイマー、抗原−ノロウイルスp粒子分子、ならびにそれらの製造および使用法

Country Status (5)

Country Link
US (2) US8486421B2 (cg-RX-API-DMAC7.html)
EP (1) EP2440582B1 (cg-RX-API-DMAC7.html)
JP (1) JP5894528B2 (cg-RX-API-DMAC7.html)
CN (2) CN107043408B (cg-RX-API-DMAC7.html)
WO (1) WO2010144602A2 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107043408B (zh) 2009-06-09 2021-02-09 儿童医院医疗中心 抗原-诺罗病毒p-结构域单体和二聚体,抗原-诺罗病毒p-粒子分子,及其制备和应用方法
JP2013517773A (ja) * 2010-01-21 2013-05-20 リゴサイト ファーマスーティカルズ,インコーポレイテッド カリシウイルスウイルス様粒子上の標的化異種抗原提示
FI122520B (fi) * 2010-10-15 2012-03-15 Vesna Blazevic Noroviruksen kapsidi ja rotaviruksen VP6-proteiini käytettäväksi yhdistelmärokotteena
US9562077B2 (en) * 2012-07-11 2017-02-07 Children's Hospital Medical Center Protein complex system for increased immunogenicity and functionality, and methods making and use
CN103304642B (zh) * 2013-06-06 2015-01-07 黑龙江八一农垦大学 猪轮状病毒δvp8*亚单位重组蛋白及其应用
US9321803B2 (en) 2013-07-12 2016-04-26 Children's Hospital Medical Center Compositions and methods for inhibiting norovirus infection
CN107034198B (zh) * 2015-07-15 2021-03-09 长春百克生物科技股份公司 一种嵌合诺如病毒p颗粒及其制备和应用
CN106220738A (zh) * 2016-07-31 2016-12-14 中国医学科学院医学生物学研究所 Ev71中和抗原表位与诺如病毒p结构域嵌合载体的构建和表达方法
US11833198B2 (en) 2017-03-28 2023-12-05 Children's Hospital Medical Center Norovirus S particle based vaccines and methods of making and using same
US12173032B2 (en) 2018-07-13 2024-12-24 The Trustees Of Indiana University Recombinant rotavirus expression system and recombinant rotaviruses
JP7190674B2 (ja) * 2018-08-23 2022-12-16 パナソニックIpマネジメント株式会社 ノロウイルスに結合する抗体、複合体、それを用いた検出装置及び検出方法
WO2021140524A1 (en) * 2020-01-08 2021-07-15 Bharat Biotech International Limited Viral vaccine compositions and methods of preparations thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4550019A (en) 1978-03-22 1985-10-29 South Africa Inventions Development Corporation Manufacture and use of fowl egg antibodies
US4769238A (en) * 1981-08-04 1988-09-06 The Regents Of The University Of California Synthesis of human virus antigens by yeast
US4916213A (en) 1983-02-22 1990-04-10 Xoma Corporation Ribosomal inhibiting protein-immunoglobulin conjugates with specificity for tumor cell surface antigens, and mixtures thereof
US4547367A (en) * 1983-12-20 1985-10-15 The United States Of America As Represented By The Department Of Health And Human Services Hepatitis B core antigen vaccine
US5643579A (en) 1984-11-01 1997-07-01 American Home Products Corporation Oral vaccines
US5338689A (en) 1987-08-24 1994-08-16 Stiftung Fur Diagnostische Forschung Method and card for detecting antigens and/or antibodies
ZA896668B (en) 1988-09-01 1990-06-27 Molecular Therapeutics Inc A human rhinovirus receptor protein that inhibits virus infectivity
US5068191A (en) 1989-08-31 1991-11-26 The Biomembrane Institute Purified histo-blood group a glycosyltransferase and antibodies thereto
CA2029219A1 (en) * 1989-11-08 1991-05-09 Mary K. Estes Methods and reagents to detect and characterize norwalk and related viruses
AU6643290A (en) * 1989-11-08 1991-06-13 Baylor College Of Medicine Methods and reagents to detect and characterize norwalk and related viruses
US6572862B1 (en) * 1989-11-08 2003-06-03 Baylor College Of Medicine Methods and reagents to detect and characterize Norwalk and related viruses
FR2677767B1 (fr) 1991-06-11 1994-10-14 Biotechnologie Ste Europeenne Procede de detection de l'infection par le virus de la diarrhee bovine, sequence nucleotidique codant pour une proteine induite par l'infection par ce virus et proteines et antigenes recombinants s'y rapportant .
AU664561B2 (en) 1991-06-21 1995-11-23 University Of Cincinnati, The Orally administrable therapeutic proteins and method of making
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
AU3972893A (en) 1992-04-03 1993-11-08 Baylor College Of Medicine Gene therapy using the intestine
US5374532A (en) 1992-08-31 1994-12-20 The Biomembrane Institute Method for determining susceptibility to escherichia coli urinary tract infections and method for diagnosing secretors and nonsecretors
US5367054A (en) 1993-04-12 1994-11-22 Stolle Research & Development Corp. Large-scale purification of egg immunoglobulin
DE4335025A1 (de) 1993-10-14 1995-04-20 Boehringer Ingelheim Int Endosomolytisch wirksame Partikel
US5750394A (en) 1994-05-20 1998-05-12 The Mount Sinai Medical Center Identification and use of antiviral compounds that inhibit interaction of host cell proteins and viral proteins required for viral replication
US6300090B1 (en) 1994-07-29 2001-10-09 The Rockefeller University Methods of use of viral vectors to deliver antigen to dendritic cells
US5861241A (en) * 1995-08-16 1999-01-19 University Of Massachusetts Monoclonal antibodies for detecting Norwalk virus
WO1997006818A1 (en) 1995-08-18 1997-02-27 Dr. Rentschler Biotechnologie Gmbh Pharmaceutical compositions for competitively inhibiting the binding of a retrovirus to the ifn-receptor and means for diagnosis of an hiv infection
US5891862A (en) 1996-03-15 1999-04-06 Geltex Pharmaceuticals, Inc. Polyvalent polymers for the treatment of rotavirus infection
IL118625A0 (en) 1996-06-11 1996-10-16 Xtl Biopharmaceuticals Limited Anti HBV antibodies
US6225290B1 (en) 1996-09-19 2001-05-01 The Regents Of The University Of California Systemic gene therapy by intestinal cell transformation
US6045854A (en) 1997-03-31 2000-04-04 Abbott Laboraties Nutritional formulations containing oligosaccharides
US20020019991A1 (en) 1998-04-30 2002-02-14 Abbott Laboratories Compositions containing an alpha 1,2-fucose linkage and uses thereof
US6593080B1 (en) * 1999-02-01 2003-07-15 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Diagnosis, prevention and treatment of calicivirus infection in humans
DE19963859A1 (de) 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
CN1330080A (zh) * 2000-06-19 2002-01-09 上海博德基因开发有限公司 一种新的多肽——人含p结构域的蛋白10和编码这种多肽的多核苷酸
US6946266B2 (en) 2000-12-20 2005-09-20 Fred Hutchinson Cancer Research Center Gene transfer in chicken bursal stem cells
WO2003003985A2 (en) 2001-07-06 2003-01-16 Sloan-Kettering Institute For Cancer Research Polyvalent conjugate vaccine for cancer
US7977098B2 (en) * 2002-05-31 2011-07-12 Children's Hospital Medical Center Antigenic binding patterns of norovirus to human histo-blood group antigens
AU2003273206B2 (en) 2002-05-31 2009-08-20 Children's Hospital Medical Center Method, composition and kit for antigenic binding of Norwalk-Like viruses
US7785871B2 (en) * 2002-10-09 2010-08-31 Intrexon Corporation DNA cloning vector plasmids and methods for their use
US20080050808A1 (en) 2002-10-09 2008-02-28 Reed Thomas D DNA modular cloning vector plasmids and methods for their use
EP1642475B1 (en) 2003-07-03 2015-08-26 Sung-Chul Sohn System and method for zone-based personalized information providing
US20070280949A1 (en) 2003-07-10 2007-12-06 Michelle Alfa Combination Therapy for Gastroenteric Diseases Caused by Microorganisms
US7879338B2 (en) 2003-07-21 2011-02-01 Boyce Thompson Institute For Plant Research Vectors and methods for immunization against norovirus using transgenic plants
JP2007537137A (ja) 2003-09-24 2007-12-20 モンタナ ステート ユニバーシティ ノロウィルスモノクローナル抗体及びペプチド
US8277819B2 (en) * 2005-06-16 2012-10-02 Children's Hospital Medical Center Norovirus particle for use as an antiviral or vaccine
US20070231320A1 (en) 2006-04-03 2007-10-04 Cook Mark E Eggs having increased antibody titer and methods for making same
US20110152263A1 (en) 2006-11-16 2011-06-23 Xi Jiang Composition and method for inhibiting norovirus infection
US8475789B2 (en) 2008-01-22 2013-07-02 Multimerics Aps Products and methods to prevent infections
EP2208641B1 (de) 2009-01-14 2011-11-02 Magna Auteca AG Antrieb für ein zu verstellendes Bauteil
CN107043408B (zh) 2009-06-09 2021-02-09 儿童医院医疗中心 抗原-诺罗病毒p-结构域单体和二聚体,抗原-诺罗病毒p-粒子分子,及其制备和应用方法

Similar Documents

Publication Publication Date Title
Fougeroux et al. Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity
Martinez-Flores et al. SARS-CoV-2 vaccines based on the spike glycoprotein and implications of new viral variants
JP7641005B2 (ja) コンジュゲート型ウイルス様粒子および抗腫瘍免疫リダイレクタとしてのその使用
Thrane et al. A novel virus-like particle based vaccine platform displaying the placental malaria antigen VAR2CSA
Raman et al. Structure-based design of peptides that self-assemble into regular polyhedral nanoparticles
JP5890407B2 (ja) 呼吸器合胞体ウイルス抗原組成物および方法
EP2308900B1 (en) Immunogenic compositions and methods of use
JP2015529678A5 (cg-RX-API-DMAC7.html)
JP2020517635A5 (cg-RX-API-DMAC7.html)
JP2011521662A5 (cg-RX-API-DMAC7.html)
Metz et al. Precisely molded nanoparticle displaying DENV-E proteins induces robust serotype-specific neutralizing antibody responses
JP5894528B2 (ja) 抗原−ノロウイルスpドメインモノマーおよびダイマー、抗原−ノロウイルスp粒子分子、ならびにそれらの製造および使用法
Metz et al. Nanoparticle delivery of a tetravalent E protein subunit vaccine induces balanced, type-specific neutralizing antibodies to each dengue virus serotype
JP2016504993A5 (cg-RX-API-DMAC7.html)
Choi et al. Oncolytic adenovirus coated with multidegradable bioreducible core-cross-linked polyethylenimine for cancer gene therapy
JP2023153851A (ja) アデノウイルスおよびアデノウイルスを使用するための方法
TW202202169A (zh) 預防嚴重急性呼吸症候群冠狀病毒第二型(sars-cov-2)感染的生物可降解奈米複合物疫苗及方法
Cacciottolo et al. Nanograms of SARS-CoV-2 spike protein delivered by exosomes induce potent neutralization of both delta and omicron variants
JP2009520758A5 (cg-RX-API-DMAC7.html)
JP2013529178A5 (cg-RX-API-DMAC7.html)
JP2015516954A (ja) 抗原性組成物および方法
JP2010508857A5 (cg-RX-API-DMAC7.html)
Ali et al. Surface cross-linking by macromolecular tethers enhances virus-like particles’ resilience to mucosal stress factors
JP6934862B2 (ja) 抗マラリア組成物および方法
Park et al. Development of self-assembled protein nanocage spatially functionalized with HA stalk as a broadly cross-reactive influenza vaccine platform